User profiles for Annabelle Ballesta

Annabelle Ballesta

Institut Curie, INSERM U900
Verified email at curie.fr
Cited by 1208

Systems chronotherapeutics

A Ballesta, PF Innominato, R Dallmann, DA Rand… - Pharmacological …, 2017 - ASPET
Chronotherapeutics aim at treating illnesses according to the endogenous biologic rhythms,
which moderate xenobiotic metabolism and cellular drug response. The molecular clocks …

Applying ecological and evolutionary theory to cancer: a long and winding road

…, R Itzykson, R Tang, F Fava, A Ballesta… - Evolutionary …, 2013 - Wiley Online Library
Since the mid 1970s, cancer has been described as a process of Darwinian evolution, with
somatic cellular selection and evolution being the fundamental processes leading to …

Systems biology, systems medicine, systems pharmacology: the what and the why

A Stéphanou, E Fanchon, PF Innominato, A Ballesta - Acta biotheoretica, 2018 - Springer
Abstract Systems biology is today such a widespread discipline that it becomes difficult to
propose a clear definition of what it really is. For some, it remains restricted to the genomic field…

Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer

…, M Bouchahda, M Haydar, A Ballesta… - Cancer …, 2018 - Wiley Online Library
Background Psychosocial symptoms often cluster together, are refractory to treatment, and
impair health‐related quality of life ( HR ‐QoL) in cancer patients. The contribution of …

[HTML][HTML] Bmal1 knockdown leans epithelial–mesenchymal balance toward epithelial properties and decreases the chemoresistance of colon carcinoma cells

…, H Acloque, A Foudi, Y Xiang, A Ballesta… - International journal of …, 2021 - mdpi.com
The circadian clock coordinates biological and physiological functions to day/night cycles.
The perturbation of the circadian clock increases cancer risk and affects cancer progression. …

[HTML][HTML] A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer

J Hesse, J Martinelli, O Aboumanify, A Ballesta… - Computational and …, 2021 - Elsevier
Scheduling anticancer drug administration over 24 h may critically impact treatment success
in a patient-specific manner. Here, we address personalization of treatment timing using a …

Circadian regulation of drug responses: toward sex-specific and personalized chronotherapy

…, E Hadadi, PF Innominato, A Ballesta - Annual review of …, 2024 - annualreviews.org
Today's challenge for precision medicine involves the integration of the impact of molecular
clocks on drug pharmacokinetics, toxicity, and efficacy toward personalized chronotherapy. …

Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: randomized multicenter EORTC 05011 …

PF Innominato, A Ballesta, Q Huang, C Focan… - Cancer …, 2020 - Wiley Online Library
The least toxic time (LTT) of irinotecan varied by up to 8 hours according to sex and genetic
background in mice. The translational relevance was investigated within a randomized trial …

Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling

S Dulong, A Ballesta, A Okyar, F Lévi - Molecular cancer therapeutics, 2015 - AACR
Cancer chronotherapy aims at enhancing tolerability and efficacy of anticancer drugs through
their delivery according to circadian clocks. However, mouse and patient data show that …

[HTML][HTML] A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery

A Ballesta, S Dulong, C Abbara, B Cohen… - PLoS computational …, 2011 - journals.plos.org
Circadian timing largely modifies efficacy and toxicity of many anticancer drugs. Recent
findings suggest that optimal circadian delivery patterns depend on the patient genetic …